Publication:

Nanoparticle Clearance: A Regulatory Summary Recommending Strengthening of the Current FDA Guidance in Assuring Long Term Safety of Nanoparticle Therapies in Cancer Patients

Loading...
Thumbnail Image

Date

2023-05-01

Published Version

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Machado, Terra Leonie. 2023. Nanoparticle Clearance: A Regulatory Summary Recommending Strengthening of the Current FDA Guidance in Assuring Long Term Safety of Nanoparticle Therapies in Cancer Patients. Master's thesis, Harvard University Division of Continuing Education.

Abstract

Cancer has complicated pathogenesis, making it one of the leading causes of mortality and morbidity. Traditional cancer treatments include targeted therapy, immunotherapy, chemotherapy, and radiation therapy. The development of nanotechnology has led to a revolution in the treatment and detection of cancer. Nanoparticles can be a better option for cancer because they have unique advantages like biocompatibility, less drug related toxicity, better stability, higher permeability and retention impact, and precise targeting. This overview discusses the factors that could affect the biodistribution and blood circulation half-life of nanoparticles (NPs) used in drug delivery systems. These variables include adjustable nanoparticle parameters such as composition, size, core characteristics, surface modifications like PEGylation and surface charge, targeted ligand functionalization, and interactions with biological barriers. Cancer currently presents a challenge to effective treatment due to its complicated pathogenesis and the drawbacks of traditional treatments such as multi-drug resistance, cytotoxicity, and lack of selectivity. Nanoparticles have unique advantages such as biocompatibility, less toxicity, better stability, higher permeability and retention effect, and precise targeting. Furthermore, drug delivery systems based on nanoparticles can help reduce cancer-related treatment resistance, which is caused by impaired apoptotic pathways, overexpression of drug efflux transporters, and hypoxic environments. Nanoparticles are also being investigated for their potential use in immunotherapy. This overview examines how NPs can be utilized to deliver drugs, how they are cleared from the body, and proposes how the FDA has set guidance for the industry for nanomaterials and the gaps for where they can do more to keep these therapies safe for use in humans

Description

Other Available Sources

Research Data

Keywords

Nanotechnology

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories